This section of the web-site contains information on medicines, advertising of which is not foreseen by the legislation. Information in this section is intended for reference only, has exclusively scientific and informative character and should not be treated as advertising information for a wide range of people. According to the current legislation, access to this information is granted to medical and pharmaceutical employees. Please confirm that you are a medical or pharmaceutical employee.


With the first symptoms of cold, such as running nose, sore throat, cough, fatigue and others, first of all it is necessary to repel pathogens which have caused these symptoms. Since common cold is caused by viruses in 90% of cases and in 10% - by bacteria, in the first days of the disease we need a drug which has both antiviral and antibacterial action. Furthermore, during cold deseases, protective functions of the body grow weak significantly, therefore we should take care of the immune system as well.

Umckalor®* is a German herbal mediine, which, due to its main ingredient i.e. Pelargonium sidoides, combines three major actions, namely: antiviral, antibacterial and immunomodulatory.

Umckalor® is the most efficient at early stages of its intake, as due to its properties, it fights off viruses and bacteria from the first day of the disease, prevents their penetration into the cell, and thereby their growth, enhances the body's defenses, promotes faster recovery and prevents complications.

Umckalor® is administered to treat acute and chronic respiratory tract and ENT diseases i.e. bronchitis, sinusitis, rhinopharyngitis, tonsillitis in adults and children from 1. The course of treatment with Umckalor against cold takes 7-10 days. It is recommended to take Umckalor from the first day of cold, thus you will speed up the healing process and prevent possible complications.

Find out more about Umckalor on

Umckalor® – first care against cold for the whole family

20 and 50 ml Umckalor solution: produced by DHU Arzneimittel GmbH & Co. KG (Germany), Marketing Authorization No. UA/6691/01/01.

*Drug advertising. Read instructions carefully and consult a doctor before use. Keep out of the reach of children.

Self-medication can be harmful to your health

First aid for the whole family if catching a cold!

Solution for oral intake, vial, 20 ml
Solution for oral intake, vial, 50 ml

Extract of Pelargonium iodides root  (1:8-10) 800 mg/1 g

Additional substances: glycerin, 85%

Extraction fluid: Ethanol, 11% (mass)

Alcohol content: 12% (mass) of alcohol

Pharmacotherapeutic group: Medications for curing cough and catarrhal diseases. ATC code: R05X.

Indications: Acute and chronic respiratory and epipharynx infections: bronchitis, sinusitis, tentorial angine, rhinopharyngitis.

Umckalor shall not be used in the cases of hypersensitivity to one of the medication components, high susceptibility to bleeding, and intaking medications inhibiting the blood clotting process. Umckalor shall not be administered to patients suffering severe liver or renal diseases (because of lacking sufficient information about using the medication in such cases).

Adverse effects:
Regarding gastrointestinal tract: stomach pain, heartburn, nausea or diarrhea – not too often; light gum bleeding – rarely.
Regarding respiratory system, thoracic organs, and mediastinum: light nasal bleeding – rarely.
Regarding skin and subcutaneous tissues/immune system: hypersensitivity reactions (including skin eruption, urticaria, skin and mucous  membrane itch) – rarely.
In extremely rare cases, severe hypersensitivity reactions may be observed in the forms of  facial oedema, dyspnea, and arterial pressure drop.
Regarding hepatobiliary system: raising liver indications – very rarely. No cause-and-effect relation between growth of these indications and administration of the drug has been found.

Currently, no interaction data are available.
Since any Umckalor effect on blood clotting parameters may not be excluded, there is some probability that it may, in case of combined use, effect results of using such indirect anticoagulants as warfarin. When carrying a placebo-controlled, double blind clinical trial with participation of healthy subjects, no interaction of Umckalor with penicillin V was observed.

Overdosage: So far, no information regarding overdosage has been found. Growth of adverse effect expression is possible.

Storage requirements:
Storage temperature shall not exceed 15 to 25ºC. In phytogenous extracts, in solution formulations, opacity may appear with time having no effect on the medication efficacy. Since Umckalor is a phytogenous medication, it may change its color and taste.

Shelf life: 2 years. After opening the vial, the medication effective life becomes equal to 3 months.

Sell condition: over the counter.

In Germany Since 1978 Umckalor
In Ukraine Since 1998 Umckalor

Pharmacodynamics. The medication contains root extract of Pelargonium sidoides, native plant of South Africa.

In animal studies, administration of the extract has shown: suppression of disease development (non-specific disease symptoms in the infection context) and antioxidant properties.

In vitro tests confirmed such effects of Umckalor:

Antimicrobial and antiviral properties:

  • moderately expressed direct antibacterial effect;
  • moderately expressed direct antiviral property;
  • raise/inhibition of A-streptococcus adhesion to desquamative/live epithelial cells;
  • inhibition of β-lactamase.

Cytoprotective Properties:

  • inhibition of leukocytal elastase;
  • antioxidant properties.

Stimulation of non-specific nocifensors:

  • stimulation of ciliated epithelium contraction rate;
  • modulation of interferon and anti-inflammatory cytokine synthesis;
  • stimulation of NK cell activity;
  • Phagocyte stimulation, expression of molecule adhesion, and chemotaxis.

To adults and children aged over 12 years: 30 drops 3 times a day.

Children aged 6 to 12 years: 20 drops 3 times a day.

Children aged 1 to 6 years: 10 drops 3 times a day.

The solution shall be taken with small amount of liquid in morning, day, and evening.

The vial shall be held vertically, with light tapping at its bottom if appropriate.

After symptoms having become less expressed, it is recommended to continue the treatment with Umckalor medication for several more days to prevent the disease recurrence. Average duration of treatment with Umckalor medication is 7 to 10 days. The overall treatment duration shall not exceed 3 weeks.

If the symptoms have not regressed in a week, high temperature has been lasting for several days, or if dyspnea and bloody sputum are observed, it is recommended to consult a doctor.

Intaking in a period of pregnancy or lactation: since lack of sufficient data regarding use of Umckalor in periods of pregnancy or lactation, it is not recommended to use the medication in such periods.

Children: since lack of sufficient data regarding use of Umckalor for treatment of sucklings, it is not recommended to use the medication for treatment children aged up to 1 year. Use of Umckalor for treatment of  younger children (up to 6 years) is recommended under doctor’s care only.

Effecting  reaction rate when driving a vehicle or working with other mechanisms: Umckalor contains 12% (by volume) of ethanol. Its effect on reaction rate, when driving vehicles or operating other mechanisms, has not been studied.


Ask a question

To prevent automated spam submissions leave this field empty.